{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:16:39Z","timestamp":1777392999008,"version":"3.51.4"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of the Report<\/jats:title>\n            <jats:p>Oxidative stress is a leading factor in the pathogenesis of idiopathic Parkinson disease (IPD). Two intrinsic antioxidative molecules, bilirubin and uric acid, are known to protect dopaminergic neurons from oxidative stress in IPD. The objective of this study was to determine the relationship between basal serum levels of 2 molecules and dopaminergic deficit assessed by dopamine transporter imaging with <jats:sup>18<\/jats:sup>F-fluorinated-<jats:italic toggle=\"yes\">N<\/jats:italic>-3-fluoropropyl-2-\u03b2-carboxymethoxy-3-\u03b2-(4-iodophenyl)nortropane ([<jats:sup>18<\/jats:sup>F]FP-CIT) PET\/CT in patients with early-stage drug-naive IPD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Cases of IPD patients who possess the levels of uric acid and bilirubin within a month from [<jats:sup>18<\/jats:sup>F]FP-CIT PET\/CT from January 2011 to December 2016 were retrospectively reviewed. As a control, the same criteria applied to patients with essential tremor (ET). PET images were analyzed using volume-of-interest templates for 12 striatal subregions and 1 occipital area, and the specific-to-nonspecific binding ratio (SNBR) was calculated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>One hundred five patients with drug-naive, early-stage IPD and 62 patients with ET were finally included. Levels of bilirubin were significantly higher in the IPD group than in controls (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.026), and bilirubin level was the factor showing the most correlations with SNBR in IPD (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001), whereas uric acid showed no such difference or relationship. Furthermore, levels of bilirubin showed a positive correlation with SNBR in more affected posterior putamen in the IPD group (Pearson correlation coefficient, <jats:italic toggle=\"yes\">\u03c1<\/jats:italic> = 0.456; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001), but a negative one in the ET group (<jats:italic toggle=\"yes\">\u03c1<\/jats:italic> = \u22120.440, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Bilirubin, not uric acid, was the most significant antioxidant marker for dopaminergic deficit in early-stage drug-naive IPD assessed by [<jats:sup>18<\/jats:sup>F]FP-CIT PET\/CT.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000002749","type":"journal-article","created":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T09:59:13Z","timestamp":1567677553000},"page":"855-859","source":"Crossref","is-referenced-by-count":10,"title":["Bilirubin-Related Differential Striatal [18F]FP-CIT Uptake in Parkinson Disease"],"prefix":"10.1097","volume":"44","author":[{"given":"Dong Yun","family":"Lee","sequence":"first","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minyoung","family":"Oh","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo-Jong","family":"Kim","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jungsu S.","family":"Oh","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun Ju","family":"Chung","sequence":"additional","affiliation":[{"name":"Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Seung","family":"Kim","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2019,9,5]]},"reference":[{"key":"bib1-20230925","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0072-9752(07)83024-7","article-title":"Oxidative stress and Parkinson's disease","volume":"83","year":"2007","journal-title":"Handb Clin Neurol"},{"key":"bib2-20230925","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/nrn983","article-title":"Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein","volume":"3","year":"2002","journal-title":"Nat Rev Neurosci"},{"key":"bib3-20230925","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1136\/jnnp-2014-309676","article-title":"Identification of novel biomarkers for Parkinson's disease by metabolomic technologies","volume":"87","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"bib4-20230925","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s12013-014-0402-x","article-title":"Lower serum bilirubin and uric acid concentrations in patients with Parkinson's disease in China","volume":"72","year":"2015","journal-title":"Cell Biochem Biophys"},{"key":"bib5-20230925","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.1073\/pnas.78.11.6858","article-title":"Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis","volume":"78","year":"1981","journal-title":"Proc Natl Acad Sci U S A"},{"key":"bib6-20230925","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1126\/science.3029864","article-title":"Bilirubin is an antioxidant of possible physiological importance","volume":"235","year":"1987","journal-title":"Science"},{"key":"bib7-20230925","first-page":"423","article-title":"Uric-acid is reduced in the substantia-nigra in Parkinsons-disease\u2014effect on dopamine oxidation","volume":"34","year":"1994","journal-title":"Brain Res Bull"},{"key":"bib8-20230925","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1006\/exnr.1997.6752","article-title":"Neural heme oxygenase-1 expression in idiopathic Parkinson's disease","volume":"150","year":"1998","journal-title":"Exp Neurol"},{"key":"bib9-20230925","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/ana.20663","article-title":"Serum uric acid levels and the risk of Parkinson disease","volume":"58","year":"2005","journal-title":"Ann Neurol"},{"key":"bib10-20230925","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF01999565","article-title":"Increased plasma bilirubin in Parkinson patients on l-dopa: evidence against the free radical hypothesis?","volume":"18","year":"1997","journal-title":"Ital J Neurol Sci"},{"key":"bib11-20230925","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1001\/archneur.2008.65.6.nct70003","article-title":"Serum urate as a predictor of clinical and radiographic progression in Parkinson disease","volume":"65","year":"2008","journal-title":"Arch Neurol"},{"key":"bib12-20230925","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/ene.12688","article-title":"Increased bilirubin levels in de novo Parkinson's disease","volume":"22","year":"2015","journal-title":"Eur J Neurol"},{"key":"bib13-20230925","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/ane.12295","article-title":"Uric acid relates to dopamine transporter availability in Parkinson's disease","volume":"131","year":"2015","journal-title":"Acta Neurol Scand"},{"key":"bib14-20230925","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1002\/mds.23741","article-title":"Serum urate and probability of dopaminergic deficit in early \u201cParkinson's disease\u201d","volume":"26","year":"2011","journal-title":"Mov Disord"},{"key":"bib15-20230925","first-page":"S2","article-title":"Diagnostic criteria for essential tremor and differential diagnosis","volume":"54","year":"2000","journal-title":"Neurology"},{"key":"bib16-20230925","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson's disease","volume":"30","year":"2015","journal-title":"Mov Disord"},{"key":"bib17-20230925","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.nucmedbio.2007.02.007","article-title":"One-step high-radiochemical-yield synthesis of [18F]FP-CIT using a protic solvent system","volume":"34","year":"2007","journal-title":"Nucl Med Biol"},{"key":"bib18-20230925","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2967\/jnumed.111.095224","article-title":"Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy","volume":"53","year":"2012","journal-title":"J Nucl Med"},{"key":"bib19-20230925","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000479627","article-title":"Precise evaluation of striatal oxidative stress corrected for severity of dopaminergic neuronal degeneration in patients with Parkinson's disease: a study with 62Cu-ATSM PET and 123I-FP-CIT SPECT","volume":"78","year":"2017","journal-title":"Eur Neurol"},{"key":"bib20-20230925","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1073\/pnas.0813132106","article-title":"Bilirubin and glutathione have complementary antioxidant and cytoprotective roles","volume":"106","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"bib21-20230925","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.abb.2004.03.006","article-title":"Biomarkers of antioxidant capacity in the hydrophilic and lipophilic compartments of human plasma","volume":"430","year":"2004","journal-title":"Arch Biochem Biophys"},{"key":"bib22-20230925","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1600-0404.2009.01261.x","article-title":"Serum heme oxygenase-1 levels are increased in Parkinson's disease but not in Alzheimer's disease","volume":"121","year":"2010","journal-title":"Acta Neurol Scand"},{"key":"bib23-20230925","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/mds.27328","article-title":"Evaluation of salivary heme oxygenase-1 as a potential biomarker of early Parkinson's disease","volume":"33","year":"2018","journal-title":"Mov Disord"},{"key":"bib24-20230925","doi-asserted-by":"crossref","first-page":"e0174644","DOI":"10.1371\/journal.pone.0174644","article-title":"Lower levels of uric acid and striatal dopamine in non-tremor dominant Parkinson's disease subtype","volume":"12","year":"2017","journal-title":"PLoS One"},{"key":"bib25-20230925","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1056\/NEJM199511023331802","article-title":"The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome","volume":"333","year":"1995","journal-title":"N Engl J Med"},{"key":"bib26-20230925","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF00712990","article-title":"Interactions of bilirubin with isolated presynaptic nerve terminals: functional effects on the uptake and release of neurotransmitters","volume":"13","year":"1993","journal-title":"Cell Mol Neurobiol"},{"key":"bib27-20230925","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1203\/00006450-199809000-00008","article-title":"Bilirubin inhibits transport of neurotransmitters in synaptic vesicles","volume":"44","year":"1998","journal-title":"Pediatr Res"},{"key":"bib28-20230925","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson's disease","volume":"24","year":"2003","journal-title":"Neurobiol Aging"},{"key":"bib29-20230925","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.parkreldis.2011.10.016","article-title":"Body mass index in Parkinson's disease: a meta-analysis","volume":"18","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"key":"bib30-20230925","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jamaneurol.2015.4265","article-title":"Association between change in body mass index, Unified Parkinson's Disease Rating Scale scores, and survival among persons with Parkinson disease. Secondary analysis of longitudinal data from NINDS Exploratory Trials in Parkinson Disease Long-term Study 1","volume":"73","year":"2016","journal-title":"JAMA Neurol"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000002749","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T06:05:24Z","timestamp":1695621924000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000002749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,5]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000002749","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9,5]]}}}